A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection
30 de janeiro de 2017 atualizado por: Hoffmann-La Roche
An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir (Tamiflu®) in the Treatment of Infants 0 to <12 Months of Age With Confirmed Influenza Infection
This study will assess the pharmacokinetics/pharmacodynamics and safety of oseltamivir [Tamiflu] therapy in infants less than 1 year of age with influenza diagnosed in the 96 hours prior to the first dose.
Patients age 3-12 months will receive 3 mg/kg, 1-3 months will receive 2.5 mg/kg, and birth to 1 month will receive 2 mg/kg twice a day for a total of 10 doses.
Patients positive for influenza virus on Day 6 will be eligible to receive continued study treatment for an additional 10 doses (5 days).
The anticipated time on study treatment is 4 weeks, and the target sample size is 65-85 male and female infants.
Visão geral do estudo
Tipo de estudo
Intervencional
Inscrição (Real)
65
Estágio
- Fase 1
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
-
Berlin, Alemanha, 13353
- CAMPUS VIRCHOW-KLINIKUM CharitéCentrum 17 Klinik f.Pädiatrie Abt.Pneumologie u.Immunologie
-
Bochum, Alemanha, 44792
- LWL-Klinik-Bochum
-
Worms, Alemanha, 67547
- Onkologische Schwerpunktpraxis Dr. Med. O. Burkhard & B. Reimann
-
-
-
-
-
Bruxelles, Bélgica, 1200
- Cliniques Universitaires St-Luc
-
-
-
-
-
Madrid, Espanha, 28905
- Hospital Universitario de Getafe; Servicio de Pediatria
-
-
La Coruña
-
Santiago de Compostela, La Coruña, Espanha, 15706
- Complejo Hospitalario Universitario de Santiago (CHUS) ; Intermedios y Urgencias Pediatricas
-
-
-
-
-
Bron, França, 69677
- Hôpital Femme Mère Enfant; Service de rhumatologie pédiatrique
-
-
-
-
Lombardia
-
Milan, Lombardia, Itália, 20122
- Fondazione Ospedale Maggiore Policlinico
-
-
-
-
-
Bydgoszcz, Polônia, 85-021
- Vitamed
-
Bydgoszcz, Polônia, 85-168
- Samodzielny Publiczny Zakład Opieki; Wcześniaków I Intensywnej Terapii
-
Debica, Polônia, 39-200
- Zespol Opieki Zdrowotnej Debica; Oddzial Dzieciecy
-
Trzebnica, Polônia, 55-100
- St Hedwig Hospital In Trzebnica
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
Não mais velho que 1 ano (Filho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- infants </=12 months of age
- laboratory confirmed diagnosis of influenza within 96 hours prior to first dose
- influenza symptoms for </=96 hours prior to first dose
Exclusion Criteria:
- preterm infants less than 40 weeks (corrected for gestational age)
- weight less than 5th percentile for age (corrected for gestational age)
- concurrent gastrointestinal conditions that preclude enteric absorption of the drug
- bronchopulmonary dysplasia/chronic lung disease on assisted ventilation at time of enrollment
- active or uncontrolled respiratory, cardiac, hepatic, CNS or renal disease at baseline
- symptomatic inborn errors of metabolism
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Oseltamivir 3 mg
infants 3 to <12 months
|
oral repeating dose
|
|
Experimental: Oseltamivir 2.5 mg
infants 1 to <3 months of age
|
oral repeating dose
|
|
Experimental: Oseltamivir 2 mg
infants 0 to 30 days (post natal) of age
|
oral repeating dose
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Steady-state Area Under the Plasma Concentration Versus Time Curve From Time Zero to 12 Hours of Oseltamivir and Oseltamivir Carboxylate
Prazo: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Oseltamivir carboxylate is active metabolite of oseltamivir.
AUC0-12 was estimated for oseltamivir and oseltamivir carboxylate by linear trapezoidal rule
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
|
Steady-state Maximum Observed Plasma Concentration of Oseltamivir and Oseltamivir Carboxylate
Prazo: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Oseltamivir carboxylate is an active metabolite of oseltamivir.
Cmax was estimated for both oseltamivir and Oseltamivir carboxylate by non-compartmental analysis.
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
|
Steady-state Minimum Observed Plasma Concentration of Oseltamivir and Oseltamivir Carboxylate
Prazo: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Oseltamivir carboxylate is active metabolite of oseltamivir.
Cmin was estimated for both oseltamivir and oseltamivir carboxylate by non-compartmental analysis
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time to the Maximum Observed Plasma Concentration of Oseltamivir and Oseltamivir Carboxylate
Prazo: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Oseltamivir carboxylate is an active metabolite of oseltamivir.Tmax was estimated using non-compartmental methods
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
|
Apparent Elimination Half Life of Oseltamivir and Oseltamivir Carboxylate
Prazo: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/-15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Elimination half-life is defined as the time required for elimination of a drug to half its plasma concentration and was computed using non-compartmental method
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/-15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
|
Apparent First-order Elimination Rate Constant of Oseltamivir and Oseltamivir Carboxylate
Prazo: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Oseltamivir carboxylate is active metabolite of oseltamivir.The apparent first-order elimination rate constant (Lambda Z) was determined by linear regression analysis of terminal data points.
A minimum of 3 data points were used for lambda Z estimation.
By reporting tool convention, if n<3, no summary statistics were calculated
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
|
Total Plasma Clearance as a Function of Bioavailability and Apparent Plasma Clearance of the Metabolite as a Function of Bioavailability (CLm/F) of Oseltamivir and Oseltamivir Carboxylate
Prazo: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Oseltamivir carboxylate is active metabolite of oseltamivir.
CL/F was calculated as dose/AUCinf, where AUCinf represents the area under the concentration-time curve of the analyte in plasma over the time interval from zero extrapolated to infinity
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
|
The Volume of Distribution as a Function of Bioavailability of Oseltamivir and Oseltamivir Carboxylate
Prazo: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Oseltamivir carboxylate is active metabolite of oseltamivir.
V/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
|
Clast of Oseltamivir and Oseltamivir Carboxylate
Prazo: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
The last measurable plasma concentration of oseltamivir and oseltamivir carboxylate was the last quantifiable concentration of oseltamivir or oseltamivir carboxylate, respectively.
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
|
Time of the Last Measurable Plasma Concentration for Oseltamivir and Oseltamivir Carboxylate
Prazo: 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
Oseltamivir carboxylate is an active metabolite of oseltamivir.
|
15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 3 if two doses taken on Day 1 or 15 minutes pre-dose; 1 hour +/- 15 minutes, 2-3, 5-7, 10-12 hours post-dose on Day 4 if one dose taken on Day 1
|
|
Number of Participants With Change From Baseline in Neurological Assessment Scores
Prazo: Baseline (Day 1); Day 3 for who received two does on Day 1 or Day 4 for who received one dose on Day 1; Day 6, Day 11, Day 18, Day 30
|
Neurological assessment was performed to assess the mental state of the participants through two scales: Infant face scale and Glasgow coma scale.
Each scale consists of 3 subscales: eye opening (ranging 1 to 4), verbal response (ranging 1 to 5), and motor responses (ranging 1 to 6).
The final score is the sum of these ranges and is scored between 3 and 15. 3 being the worst, and 15 the best.
Change from baseline is change of final score post-baseline minus the final score at baseline.
|
Baseline (Day 1); Day 3 for who received two does on Day 1 or Day 4 for who received one dose on Day 1; Day 6, Day 11, Day 18, Day 30
|
|
Median Time to Cessation of Viral Shedding in Participants With Positive Culture at Baseline
Prazo: Days 1, 3 or 4, 6, 11, 18, and 30
|
Median time to cessation of viral shedding was calculated for all patients with positive by culture / by polymerase chain reaction (PCR) at baseline using all data points between the start of the treatment and the 1st time point of negative culture without subsequent positive culture results.
These time-to event analyses were only performed for the viral titre.
|
Days 1, 3 or 4, 6, 11, 18, and 30
|
|
Number of Participants With Virus Shedding by Virus Type
Prazo: Baseline (Day 1), Day3/4, Day 6, Day 11, Day 18+/-2 days, Day 30+/-2 days
|
The viral titer was measured by culture and reported in log10 (50% tissue culture infective dose [TCID50]).
The viral load was analyzed by PCR and reported as log10 particles/mL.
The number of patients positive for viral shedding by virus sub-type was measured on specified days from baseline to last visit on Day 30.
|
Baseline (Day 1), Day3/4, Day 6, Day 11, Day 18+/-2 days, Day 30+/-2 days
|
|
Time to Resolution of Fever in Participants With Fever at the Baseline
Prazo: Days 1 to 11; Day 18; Day 30
|
This was performed for all participants who had fever at baseline.
Fever is defined as body temperature >37.0 degree Celsius.
Rectal temperature is converted by subtracting 1 degree Celsius.
Time to Resolution of Fever was defined as the time from the initiation of treatment to first time the afebrile state was reached and maintained for at least 21.5 hours, where afebrile state was defined as axillary temperature ≤ 37 degree Celsius.
|
Days 1 to 11; Day 18; Day 30
|
|
Percentage of Participants With Decline of Body Temperature to the Afebrile State
Prazo: Baseline (Day 1), Day3/4, Day 6, Day 11, Day 18+/-2 days, Day 30+/-2 days
|
This was performed for all participants who had fever at baseline Fever is defined as body temperature >37.0ºC.
Rectal temperature is converted by subtracting 1 ºC.
The rate of decline of body temperature was calculated as the slope of body temperature between the baseline temperature and the 1st temperature below 37°C.
Participants with decline in body temperature were considered to have no fever; however, participants who did not show any decline in body temperature were considered to have persisting fever.
|
Baseline (Day 1), Day3/4, Day 6, Day 11, Day 18+/-2 days, Day 30+/-2 days
|
|
Number of Participants With Adverse Events, Serious Adverse Events and Secondary Illness
Prazo: Up to 3 days after the last dose of oseltamivir (Approximately 14 days)
|
An Adverse Event (AEs) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product.
An Serious Adverse Event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect.
Secondary illnesses were influenza disease-related events, namely bronchitis, pneumonia, otitis media, and sinusitis that resolved without sequelae.
Adverse events, serious adverse events, and secondary illness are reported for on-treatment period (from the first dose of oseltamivir upto 3 days after the last dose of oseltamivir [Approximately 14 days].
|
Up to 3 days after the last dose of oseltamivir (Approximately 14 days)
|
|
Number of Participants Showing Within-patient Variability in Vital Signs
Prazo: Post baseline, Day 3, 4, 6, 11, 18+/- 2 days, 30+/-2 days
|
Systolic blood pressure, diastolic blood pressure, pulse rate, respiratory rate, and heart rate were examined for any consistent within-patient post-baseline changes.
|
Post baseline, Day 3, 4, 6, 11, 18+/- 2 days, 30+/-2 days
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de janeiro de 2011
Conclusão Primária (Real)
1 de abril de 2012
Conclusão do estudo (Real)
1 de abril de 2012
Datas de inscrição no estudo
Enviado pela primeira vez
30 de setembro de 2009
Enviado pela primeira vez que atendeu aos critérios de CQ
30 de setembro de 2009
Primeira postagem (Estimativa)
2 de outubro de 2009
Atualizações de registro de estudo
Última Atualização Postada (Real)
20 de março de 2017
Última atualização enviada que atendeu aos critérios de controle de qualidade
30 de janeiro de 2017
Última verificação
1 de janeiro de 2017
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- WP22849
- 2009-014365-12
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .